Media

Optimizing mHSPC Care and Collaboration for Triplet Therapy - Jason Hafron & Elisabeth Heath

Details
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores the importance of collaboration between urology and medical oncology, particularly in administering triplet therapy. Dr. Hafron highlights the evolution of their partnership, emphasizing shared knowledge and pati...

New Prostate Cancer Risk Variants Identified in Expanded Multi-Ancestry GWAS Meta-Analysis - Anqi Wang

Details
Anqi Wang unveils findings from her study published in Nature Genetics. Dr. Wang's research marks a significant advance in understanding the genetic landscape of prostate cancer, identifying a total of 451 independent risk loci, including 187 novel variants, through an expanded multi-ancestry meta-analysis. This study not only enlarges the scope of known genetic risk factors but also emphasizes th...

Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua

Details
Sam Chang converses with Trinity Bivalacqua about treatments in non-muscle invasive bladder cancer, focusing on Cretostimogene grenadenorepvec (Creto), an oncolytic adenovirus, CG0070. Dr. Bivalacqua discusses trials exploring Creto's efficacy in managing BCG-unresponsive CIS, emphasizing its dual mechanism of action: direct tumor lysis and immune system activation. Initial results from the BOND-0...

Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram

Details
Ashish Kamat is joined by Gautam Jayram to unravel the complexities of BCG unresponsiveness in bladder cancer treatment. Dr. Jayram emphasizes the importance of understanding what constitutes adequate BCG treatment, highlighting the necessity of more than just six initial doses for accurate classification of BCG unresponsiveness. He sheds light on the challenges and disparities in BCG access, part...

Plant-Based Diet Associated with Better Quality of Life in Prostate Cancer Survivors - Stacy Loeb

Details
Alicia Morgans discusses a study with Stacy Loeb, exploring the impact of a plant-based diet on prostate cancer survivors, based on Loeb's paper published in Cancer. Dr. Loeb, motivated by clinical observations and previous findings, delves into a large cohort study from the Health Professionals Follow-Up Study to examine diet's effect on sexual and urinary function among over 3,500 prostate cance...

Novel Computational Approach Identifies NME2-MYC Axis as Biomarker and Therapeutic Target in Enzalutamide-Resistant CRPC - Antonina Mitrofanova

Details
Antonina Mitrofanova delves into her team's research published in Nature Communications. The study uncovers the NME2 and MYC programs as pivotal markers of enzalutamide resistance in castration-resistant prostate cancer (CRPC). Dr. Mitrofanova's team embarked on this journey following observations that patients with elevated MYC levels showed increased resistance to androgen receptor signal inhibi...

ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen delve into the significance of racial disparities in prostate cancer treatment through a subgroup analysis of the ARASENS trial, which notably focused on Black patients. This pivotal trial assessed the efficacy of adding darolutamide to ADT and docetaxel in metastatic hormone-sensitive prostate cancer, revealing that Black patients, despite historically higher morta...

Care for Patients with Nonmetastatic Castration-Resistant Prostate Cancer - Hanan Goldberg

Details
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this patient category. They ponder the treatment conundrum posed by early detection of metastasis, not covered under current FDA approvals for medications like enzalutamide, apalutamide, and darolutamide, which have...

Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore

Details
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity of...

GU Cancer Highlights at the Upcoming 2024 AUA Annual Meeting - David Penson

Details
Sam Chang hosts David Penson to shed light on the anticipated AUA 2024 meeting in San Antonio, focusing on the fresh, innovative sessions designed to elevate clinical practice. Dr. Penson introduces the P2 program—Practice-changing, Paradigm-shifting Research—aimed at spotlighting pivotal new clinical trials. With an impressive submission of about 90 studies, the program is set to feature eight gr...